These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1746075)

  • 41. Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats.
    Lee DS; Kim SJ; Choi GW; Lee YB; Cho HY
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29662027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic evaluation of the new prolonged-release leuprorelin acetate microspheres for injection compared with Enantone® in healthy Chinese male volunteers.
    Zhou H; Xie J; Zhu X; Li X; Yu X; Zhang Y; Su Y; He C; Zhu M; Li XL; Liu Y; Chen J; Cheng D; Chen M; Wang Y; Ge Q; Fan L; Wang Y; Shao Z; Liu B; Shan R; Dai X; Wang H; Wang H
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1149-1156. PubMed ID: 34372746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
    Dijkman GA; Debruyne FM; Fernandez del Moral P; Plasman JW; Hoefakker JW; Idema JG; Sykes M
    Eur Urol; 1994; 26 Suppl 1():1-2. PubMed ID: 7737253
    [No Abstract]   [Full Text] [Related]  

  • 44. The management of a case of treatment-resistant paraphilia with a long-acting LHRH agonist.
    Dickey R
    Can J Psychiatry; 1992 Oct; 37(8):567-9. PubMed ID: 1423159
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symposium on androgen action in prostate cancer.
    Tindall D; Horne FM; Hruszkewycz A; Mohla S; Shuman M; Wang Z; Kantoff P
    Cancer Res; 2004 Oct; 64(19):7178-80. PubMed ID: 15466216
    [No Abstract]   [Full Text] [Related]  

  • 46. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Na KH; Dani BA; Jiang G; Thanoo BC; DeLuca PP
    Pharm Res; 2002 Apr; 19(4):546-50. PubMed ID: 12033393
    [No Abstract]   [Full Text] [Related]  

  • 47. Depot leuprorelin acetate-induced granulomas manifested as persistent suppurative nodules.
    Ferran M; Giménez-Arnau A; Toll A; Yébenes M; Baena V; Lloreta J; Pujol RM
    Acta Derm Venereol; 2006; 86(5):453-5. PubMed ID: 16955197
    [No Abstract]   [Full Text] [Related]  

  • 48. Hormone dependency and histological types of prostatic carcinoma.
    Schubert GF; Völter D; Ziegler H
    Int Urol Nephrol; 1981; 13(3):271-4. PubMed ID: 7327901
    [No Abstract]   [Full Text] [Related]  

  • 49. Deferred treatment in prostatic cancer.
    Newling DW; Hall RR; Powell PH
    Lancet; 1986 Aug; 2(8501):278-9. PubMed ID: 2874294
    [No Abstract]   [Full Text] [Related]  

  • 50. [Advancements in the diagnosis and therapy of prostate neoplasms. International symposium Enantone/Prostop (Leuprorelin-Depot). Hamburg, 7 March 1992].
    Urologe A; 1992 May; 31(3 Suppl):1-12. PubMed ID: 1352652
    [No Abstract]   [Full Text] [Related]  

  • 51. Prostate cancer: are we under the lee?
    Kurth KH
    Urol Res; 1997; 25 Suppl 2():S51-2. PubMed ID: 9144886
    [No Abstract]   [Full Text] [Related]  

  • 52. Hormone-refractory prostate cancer: an emerging epidemic. Proceedings from a roundtable workshop. Philadelphia, Pennsylvania, May 22, 1996.
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):1-62. PubMed ID: 9011943
    [No Abstract]   [Full Text] [Related]  

  • 53. [Delayed action effect of pentapyrrolidinium bitartrate (ansolysene) and of 1-[2-(N, N-diethyl-N-methylamino)-ethoxyethyl]-1-methylpyrrolidine diiodide (Sy-108) in subcutaneous injections].
    FROMMEL E; VINCENT D; RADOUCO-THOMAS C; VON ALLMEN E; VALLETTE F
    Helv Physiol Pharmacol Acta; 1955; 13(3):264-9. PubMed ID: 13306105
    [No Abstract]   [Full Text] [Related]  

  • 54. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 55. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 56. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Hormone kinetics in suppression with monthly Enantone depot preparations].
    Schilling A
    Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075
    [No Abstract]   [Full Text] [Related]  

  • 58. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.